Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss

International Journal of Obesity

Volumn 21, Issue 2, 1997, Pages 97-102

  Maheux, P ^a   Ducros, F ^a   Bourque, J ^a   Garon, J ^a   Chiasson, J L ^a,b  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Fluoxetine; Insulin resistance; Obesity

Indexed keywords

FLUOXETINE; INSULIN; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET; DOUBLE BLIND PROCEDURE; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TRANSPORT; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; METABOLIC CLEARANCE RATE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; WEIGHT REDUCTION;

EID: 0031018487     PISSN: 03070565     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijo.0800372     Document Type: Article

References (20)

1. De Fronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease Diabetes Care 1991; 14: 173-194.
2. Verdy M et al. Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect Int J Obes 1983; 7: 289-297.
3. Scheen AJ, Paolisso G, Salvatore T, Lefèbvre PJ. Improvement of insulin-induced glucose disposal in obese patients with NIDDM after 1-wk treatment with d-fenfluramine Diabetes Care 1991; 14: 325-332.
4. Cohn JB, Wilcox C. A comparison of fluoxetine, imipramine, and placebo in patients with major depressive disorder J Clin Psychiatry 1985; 46: 26-31.
5. Wong DT, Bymaster FP, Horng JS, Meloy BB. A new selective inhibitor for uptake of serotonin into synaptosomes of rat brain: 3-(p-trifluromethylphenoxy)-N-methy1-3-phenyl-propylamine J Pharmacol Exp Ther 1975; 193: 804-811.
6. Levine LR, Rosenblatt S, Bosomworth J. Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity Int J Obes 1987; 11 (suppl 1): 185-190.
7. Levine LR et al. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study Int J Obes 1989; 13: 635-645.
8. Chiasson JL et al. Fluoxetine has potential in obese NIDDM-Multi-center Canadian trial Diabetes 1989; 38 (suppl. 2): 154A.
9. Kutnowski M, Daubresse JC, Friedman H, Kolanowski J, Krzentowski G, Scheen A, et al. Fluoxetine therapy in obese diabetic and glucose intolerant patients Int J Obes 1992; 16 (suppl 4): S63-S66.
10. Gray DS, Fujioka K, Devine W, Bray GA. Fluoxetine treatment of the obese diabetic Int J Obes 1992; 16: 193-198.
11. O'Kane M, Wiles PG, Wales JK. Fluoxetine in the treatment of obese type 2 diabetic patients Diabetic Med 1993; 11: 105-110.
12. Willey KA, Molyneaux LM, Overland JE, Yue DK. The effects of dexfenfluramine on blood glucose control in patients with type 2 diabetes Diabetic Med 1992; 9: 341-343.
13. Pestell RG, et al.. Fenfluramine increases insulin action in patients with NIDDM Diabetes Care 1989; 12: 252-257.
14. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance Diabetes 1979; 28: 1039-1957.
15. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance Am J Physiol 1979; 237: E214-E223.
16. Cole RA, Soeldner JS, Dunn PJ, Bunn HF. A rapid method for the determination of glycosylated hemoglobin using high pressure liquid chromatography Metabolism 1978; 27: 289-301.
17. Potter van Loon BJ, et al. Fluoxetine increases insulin action in obese nondiabetic and in obese non-insulin-dependent diabetic individuals Int J Obes 1992; 16: 79-85.
18. Brindley DN. Metabolic and hormonal effects of dexfenfluramine in stress situations Clin Neuropharmacol 1988; 11 (suppl. 1): 586-589.
19. Jorgensen KD. Actions of fenfluramine on glucose uptake in vitro and in vivo Acta Pharmacol Toxicol 1977; 40: 401-417.
20. 14C-glucose by human adipose tissue Postgrad Med J 1975; 51 (suppl. 1): 110-114.